New drug shows promise for repairing damaged hearts in stable heart failure patients

NCT ID NCT07405944

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the drug vericiguat can help repair the hearts of adults with stable heart failure with reduced ejection fraction (HFrEF). Researchers will compare people taking vericiguat plus standard care to those on standard care alone, measuring changes in heart structure and function over 12 months. The study involves 60 participants and includes blood tests, heart scans, and glucose tests to understand how the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure Fibrosis Inflammation Insulin Resistance systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Centre Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact